Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126631441 | 12663144 | 1 | I | 20151027 | 0 | 20160817 | 20160817 | DIR | 15.00 | YR | M | N | 175.00000 | LBS | 20160816 | N | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126631441 | 12663144 | 1 | PS | HUMALOG | INSULIN LISPRO | 1 | Subcutaneous | GIVEN INTO/UNDER THE SKIN | Y | Y | 0 | ||||||||
| 126631441 | 12663144 | 3 | C | NOVOLOG IN OMNIPOD PUMP | 2 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126631441 | 12663144 | 1 | Type 1 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126631441 | 12663144 | HO |
| 126631441 | 12663144 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126631441 | 12663144 | Blood glucose increased | |
| 126631441 | 12663144 | Contraindicated product administered | |
| 126631441 | 12663144 | Documented hypersensitivity to administered product | |
| 126631441 | 12663144 | Malaise | |
| 126631441 | 12663144 | Syncope | |
| 126631441 | 12663144 | Urticaria | |
| 126631441 | 12663144 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126631441 | 12663144 | 1 | 20050401 | 20151026 | 0 |